CTRI/2022/01/039445招募中3 期
ongterm Single versus Dual Antiplatelet Therapy In Patients With Ischemic Stroke due to Intracranial Atherosclerotic Disease: A Randomized Trial. - STENOSIS
Dr Rohit Bhatia0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age 18 years and above.
- •2.Patients with an acute ischemic stroke, OR a recent AIS OR TIA within 3 months from onset AND who have been started on DAPT with aspirin and clopidogrel within 15 days of the stroke/TIA onset and have been compliant on treatment and yet to complete 3 months of DAPT. All patients need to be on DAPT with aspirin and clopidogrel for 3 months at the time of randomization.
- •3.Symptomatic ICAD greater than or equal to 50% in intracranial vessels on CT Angiogram or contrast MR angiogram, or Digital Subtraction Angiography including M1 MCA, M2 MCA, ACA A1 , PCA P1, intracranial VA and Basilar artery.
- •4.mRS upto 4.
- •5.Informed consent.
- •6. Patients with a previous history of untreated stroke/TIA, at the discretion of the treating
排除标准
- •1.Stroke/ TIA more than 3 months at time of presentation.
- •2.Not started on DAPT with aspirin and clopidogrel within 15 days of stroke/ TIA onset.
- •3.Patients with an intracerebral hemorrhage.
- •4.Indication for DAPT other than the current stroke/ TIA; for example, patient with CAD and Post PTCA.
- •5.Patients with recurrent stroke/TIA, on treatment following the initial event.
- •6.Patients with moderate to severe tandem stenosis of extracranial common carotid, internal carotid or vertebral arteries.
- •7.Patients with intracranial arterial stenting.
- •8.Cardioembolic stroke.
- •9.Patient with a known autoimmune disease or any other immunological disease that may be interfering with the interpretation and cause of etiology of intracranial stenosis.
- •10.Patients with Moya-Moya disease.
- •11.Patients with focal intracranial arterial dissection.
- •12.Any etiology other than atherosclerotic disease as the cause of intracranial arterial stenosis as perceived by the investigator.
- •13.Patients with intracranial vasculitis as the cause of intracranial vascular disease.
- •14.Recent past history or clinical presentation of ICH, subarachnoid hemorrhage (SAH), arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm.
- •15. Current use of oral anticoagulants.
- •16.Pregnancy
- •17.Hereditary or acquired hemorrhagic diathesis
- •18.Gastrointestinal or urinary bleeding within the preceding 21 days
- •19.Major surgery within the preceding 14 days.
- •20.Any comorbid serious illness which is likely to interfere with the treatment and /or life expectancy.
- •21.Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
- •22.Any modification of treatment judged during the course of the trial, which is likely to interfere with the continuation of the medications and results of the study.
研究者
相似试验
进行中（未招募）
1 期
Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgeryEUCTR2017-001754-33-ITIVERSITÀ CAMPUS BIO-MEDICO DI ROMA800
已完成
不适用
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)Coronary Artery DiseaseJPRN-UMIN000006698PO Associations for Establishment of Evidence in Interventions4,598
招募中
4 期
Single versus dual antiplatelet therapy for feMOrOpopliTeal lesion treated witH paclItaxEl-eluting device.Symptomatic arteriosclerosis obliteransJPRN-jRCTs031220617Soga Yoshimitsu400
已完成
不适用
Impact of 1-month Dual Antiplatelet Therapy After Treatment with Drug-Coated Balloon for Femoropopliteal Artery DiseaseArteriosclerosis obliteransJPRN-UMIN000034867Hyogo College of Medicine151
进行中（未招募）
不适用
Clinical trial to evaluate treatment after percutaneous aortic valve implantatioEUCTR2011-005784-24-ESAndres Iñiguez Romo120